Dysfunctional HDL as a diagnostic and therapeutic target

Area of Science:

• Cardiovascular Science
• Biochemistry
• Immunology

Background:

• High-density lipoprotein (HDL) exerts atheroprotective effects through reverse cholesterol transport and anti-inflammatory actions.
• However, HDL functionality is heterogeneous, and HDL, particularly apolipoprotein A-I (apoAI), can become dysfunctional or proinflammatory, contributing to atherosclerosis.
• Posttranslational modifications of apoAI significantly impact its function.

Purpose of the Study:

• To investigate the impact of myeloperoxidase (MPO) modification on apoAI function.
• To understand the molecular changes induced by MPO modification of apoAI.
• To explore the potential for developing modified apoAI and clinical markers for HDL dysfunction.

Main Methods:

• Detailed molecular studies of apoAI modification by myeloperoxidase.
• Analysis of functional changes in apoAI, specifically its role as a cholesterol acceptor.
• Investigation of molecular alterations resulting from MPO-mediated apoAI damage.

Main Results:

• Myeloperoxidase modification of apoAI leads to impaired cholesterol acceptor function.
• Specific molecular changes induced by MPO in apoAI have been elucidated.
• These modifications can transform HDL from a protective to a potentially atherogenic factor.

Conclusions:

• Dysfunctional HDL, particularly MPO-modified apoAI, plays a role in promoting atherosclerosis.
• Understanding these molecular modifications is crucial for developing therapeutic strategies.
• The development of oxidant-resistant apoAI and clinical measures of HDL dysfunction may serve as treatment criteria for atherosclerosis.